The company commenced exports of Lamotrigine to the EU market. TORRENTPH`s sister concern, Torrent Gujarat Biotech was established in 1992 for producing Penicillin through fermentation technology developed by the Torrent group. TORRENTPH, with an R&D expenditure of Rs 673.2 million (14.3% of turnover) has set up an R&D center engaged in the discovery of new chemical entities for vascular complications and metabolic disorders. The company has taken up a project in collaboration with AstraZeneca. The company is also subject to DPCO (drug price control order - currently applicable to 24 drugs) under which there are three tiers of regulations - on bulk drugs, on formulations and on overall profitability.